Although significant progress has been made in the implementation of new breast cancer
treatments over the last three decades, this neoplasm annually continues to show high …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

PURPOSE To determine the updated long-term outcomes of the Addition of Ovarian
Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who …

PURPOSE The addition of ovarian function suppression (OFS) for 5 years to tamoxifen
(TAM) for treatment of premenopausal patients with breast cancer after completion of …

Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced
hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors …

Purpose: Tamoxifen remains an important hormonal therapy for ER-positive breast cancer;
however, development of resistance is a major obstacle in clinics. Here, we aimed to identify …

Background Approximately 80% of breast cancers amongst premenopausal women are
hormone receptor‐positive. Adjuvant endocrine therapy is an integral component of care for …

In the era of precision medicine, the prediction of ovarian function recovery from
chemotherapy-induced amenorrhoea using feasible biological markers may be helpful to …

Background Adding ovarian function suppression (OFS) after chemotherapy improves
survival in young women with moderate-and high-risk breast cancer. Assessment of ovarian …

Background Chemo-endocrine therapy can lead to various side effects associated with
ovarian dysfunction. Predicting menstrual recovery is necessary to discuss the treatment …